Evotec AG (EVTCY) Upgraded by Zacks Investment Research to Buy

Evotec AG (EVTCY) Upgraded by Zacks Investment Research to Buy


The brokerage currently has a $56.00 target price on the stock. Zacks Investment Research 's target price would indicate a potential upside of 20.66% from the company's previous close.



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога